Figure 4 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T

<p>Black race and TLR1-602I SNP associate with stronger responses to TLR1/2 stimulation. <b>A,</b> Supernatant cytokine release separated by Black (<i>n</i> = 15) vs. White (<i>n</i> = 91) for each stimulation normalized to fold mock treatment control in the PRIME study; (*) Mann–Whitney test <i>P</i> < 0.05. <b>B,</b> TLR1-602 genotypes for each patient with sufficient DNA (<i>n</i> = 88 White; <i>n</i> = 15 Black) were tested by PCR-RFLP; percentages of I/I or I/S vs. S/S by race are shown. <b>C,</b> Mean fold mock control cytokine induction by genotype is shown for each stimulus; asterisks indicate significant FDR-corrected unpaired <i>t</i> tests <i>Q</i> < 0.05 (two-tailed). <b>D,</b> Mean fold mock control TLR1/2 induced cytokine induction by genotype for White vs. Black (all I/I or I/S); FDR-adjusted unpaired <i>t</i> test <i>Q</i> < 0.05 vs. White S/S (*) or vs. all other groups (#). <b>E,</b> Heatmaps depict −log (<i>P</i> values) from comparisons in <b>B</b> (cytokine induction by race) or <b>C</b> (cytokine induction by TLR1 SNP status) for each cytokine and treatment. See Supplementary Fig. S6 for extended data.</p>

Duke Scholars

Author Andrew John Armstrong Medicine, Medical Oncology

Author Smita K Nair Surgery, Surgical Sciences

Author Michael Dee Gunn Medicine, Cardiology

Author Michael Brown Neurosurgery, Neuro-Oncology